Please login to the form below

Not currently logged in
Email:
Password:

NewLink Genetics

This page shows the latest NewLink Genetics news and features for those working in and with pharma, biotech and healthcare.

BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace

BMS pulls IDO inhibitor trials as Incyte-prompted rout gathers pace

The Incyte trial failure was swiftly followed by a decision by NewLink Genetics to review the status of its own IDO1 programme, headed by indoximod and NLG802, and the company later

Latest news

  • Incyte/Merck trial failure bodes ill for IDO class Incyte/Merck trial failure bodes ill for IDO class

    but also other companies developing drugs against the target such as Bristol-Myers Squibb (BMS) and NewLink Genetics, which both have candidates in late-stage trials. ... note when describing the probability of success with the approach over the past

  • Aduro pancreatic cancer vaccine trial disappoints Aduro pancreatic cancer vaccine trial disappoints

    News that Aduro's combination product failed to meet its objectives in the phase IIb ECLIPSE trial comes just a few days after NewLink Genetics announced it was abandoning development of

  • NewLink pancreatic cancer vaccine flunks phase III test NewLink pancreatic cancer vaccine flunks phase III test

    NewLink Genetics is under pressure after its pancreatic cancer vaccine fared poorly in a phase III trial, raising doubts about its R&D platform. ... Shares in NewLink lost more than a third of their value in after-hours trading.

  • Merck & Co buys IOmet to boost immuno-oncology tech Merck & Co buys IOmet to boost immuno-oncology tech

    NewLink Genetics also has trials of a candidate called indoximod ongoing in a range of cancers and forged a $250m alliance with Genentech for follow-up compound GDC-0919 in 2014.

  • Ebola vaccine completely effective, say researchers Ebola vaccine completely effective, say researchers

    expectations. The rVSV-ZEBOV candidate developed by Merck &Co and NewLink Genetics seemed to protect subjects who had been in close proximity to an infected Ebola patient from the virus, with ... Merck bought the rights to NewLink's vaccine in November

More from news
Approximately 3 fully matching, plus 13 partially matching documents found.

Latest Intelligence

  • Communicating in a crisis Communicating in a crisis

    November 2014. Merck &Co buys rights to Ebola vaccine from NewLink Genetics .

  • Deal Watch table for October 2014 Deal Watch table for October 2014

    2, 600. NewLink Genetics/Genentech. Collaboration and licence. For development of NLG919 and next generation IDO pathway inhibitors.

  • Pharma deals during October 2014 Pharma deals during October 2014

    But the classic licence deal lives on. Several classic licences were reported this month, notably NewLink Genetics and Genentech; Curetech and Medivation; Forendo and Apricus as well as Lexicon and Ipsen. ... Leading the pack, NewLink Genetics secured a

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics